GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program
Links shared publicly online about this topic.
- 0total visits
GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program
GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's Respiratory Syncytial Virus (RSV) vaccine program.
View full resource at news-medical.net
Most Recently Shared on May 4, 2012 at 7:49 am By:
Malaria News: GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program: GenVec, Inc. announced ... http://t.co/gNyTfZNU
Also Shared By:
Advertisement
News-Medical.Net
@NewsMedical
GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program: GenVec, Inc. announced today that it ... http://t.co/jltN39Bf
1 year ago...